Clinical observation on chemotherapy combined with modified Yiyanxiao Formula in treating patients of pancreatic cancer with peritoneal metastasis

LI Fulong; QIN Yiwen; WANG Hongwei; NI Hongmei; TANG Jin; DENG Yuhai; FANG Shengquan

doi:10.16306/j.1008-861x.2023.01.003

您当前的位置：

首页 >

文章列表页 >

Clinical observation on chemotherapy combined with modified Yiyanxiao Formula in treating patients of pancreatic cancer with peritoneal metastasis

Special column on anti-tumor of traditional Chinese medicine | 更新时间：2023-02-14

- Clinical observation on chemotherapy combined with modified Yiyanxiao Formula in treating patients of pancreatic cancer with peritoneal metastasis
- Academic Journal of Shanghai University of Traditional Chinese Medicine Vol. 37, Issue 1, Pages: 17-22(2023)
- 作者机构：
  
  1.上海中医药大学附属岳阳中西医结合医院（上海　200437）
  2.上海中医药大学（上海　201203）
- 作者简介：
- 基金信息：
- DOI：10.16306/j.1008-861x.2023.01.003
  CLC：
扫描看全文
李富龙,秦艺文,王宏伟等.化疗联合中药胰岩消方加减治疗胰腺癌腹膜转移的临床观察[J].上海中医药大学学报,2023,37(01):17-22.

LI Fulong,QIN Yiwen,WANG Hongwei,et al.Clinical observation on chemotherapy combined with modified Yiyanxiao Formula in treating patients of pancreatic cancer with peritoneal metastasis[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2023,37(01):17-22.
李富龙,秦艺文,王宏伟等.化疗联合中药胰岩消方加减治疗胰腺癌腹膜转移的临床观察[J].上海中医药大学学报,2023,37(01):17-22. DOI： 10.16306/j.1008-861x.2023.01.003.

LI Fulong,QIN Yiwen,WANG Hongwei,et al.Clinical observation on chemotherapy combined with modified Yiyanxiao Formula in treating patients of pancreatic cancer with peritoneal metastasis[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2023,37(01):17-22. DOI： 10.16306/j.1008-861x.2023.01.003.

摘要

目的,2,观察化疗联合胰岩消方加减治疗胰腺癌腹膜转移患者的临床疗效。,方法,2,纳入68例胰腺癌腹膜转移患者，随机分为对照组和治疗组，每组各34例。两组患者均予吉西他滨静脉滴注结合顺铂腹腔灌注化疗， 21 d为1个疗程，共治疗2个疗程。在此基础上，治疗组患者予以胰岩消方加减口服。治疗前后检测并比较两组患者的肿瘤标志物［包括糖类抗原199（CA199）、癌胚抗原（CEA）、糖类抗原125（CA125）］及炎性细胞因子［包括白介素-1β（IL-1β）、肿瘤坏死因子-α（TNF-α）、IL-6］水平；评价两组患者的临床疗效；比较两组患者的中医症状总积分和不良反应发生率。,结果,2,①治疗后，治疗组和对照组的疾病控制率分别为64.7%、44.1%，治疗组的疾病控制率高于对照组（,P,<,0.05）；治疗组和对照组的疾病缓解率分别为8.8%、5.9%，两组比较差异无统计学意义（,P,>,0.05）。②治疗后，两组患者的中医症状总积分较治疗前均降低（,P,<,0.05），且治疗组患者的积分低于对照组（,P,<,0.05）。③治疗后，两组患者的CA199、CEA水平较治疗前均明显降低（,P,<,0.05），且治疗组患者的CA199水平低于对照组（,P,<,0.05）。④治疗后，两组患者的IL-1β、IL-6水平较治疗前均降低（,P,<,0.05），治疗组患者的TNF-α水平较治疗前亦降低（,P,<,0.05），且治疗组患者的IL-1β、IL-6水平低于对照组（,P,<,0.05）。⑤治疗过程中，治疗组的不良反应发生率为44.1%，对照组为76.5%，治疗组的不良反应发生率明显低于对照组（,P,<,0.05）。,结论,2,化疗联合中药胰岩消方加减治疗胰腺癌腹膜转移患者，可有效抑制肿瘤标志物及炎性细胞因子表达，改善患者的临床症状，提高疾病控制率，降低化疗不良反应发生率。

Abstract

Objective： To observe the clinical efficacy of chemotherapy combined with modified Yiyanxiao Formula in the treatment of pancreatic cancer with peritoneal metastasis.,Methods,2,Sixty-eight patients of pancreatic cancer with peritoneal metastasis were enrolled and randomly divided into the control group and treatment group， 34 cases in each group. The patients in both groups were treated with gemcitabine intravenous drip combined with cisplatin intraperitoneal perfusion chemotherapy. Twenty-one was a course of treatment and a total of two courses of treatment was performed. Based on above， the patients in the treatment group were treated with modified Yiyanxiao Formula orally. Before and after treatment， the levels of the tumor markers including carbohydrate antigen 199 （CA199）， carcinoembryonic antigen （CEA） and carbohydrate antigen 125 （CA125）， and the inflammatory cytokines including interleukin-1β（IL-1β）， tumor necrosis factor-α （TNF-α） and IL-6 in the two groups were detected and compared. The clinical efficacy of the two groups was evaluated. The total scores of traditional Chinese medical symptoms and the incidence of adverse reactions were compared between the two groups.,Results,2,①After treatment， the disease control rates of the treatment group and the control group were 64.7% and 44.1% respectively， and the disease control rate of the treatment group was higher than that of the control group （,P,<,0.05）. The disease remission rates of the treatment group and the control group were 8.8% and 5.9% respectively， with no statistically significant difference between the two groups （,P,>,0.05）. ②After treatment， the total scores of traditional Chinese medical symptoms in both groups were decreased compared with those before treatment （,P,<,0.05）， and the score of the patient in the treatment group was lower than that in the control group （,P,<,0.05）. ③After treatment， the levels of CA199 and CEA in the two groups were significantly decreased compared with those before treatment （,P,<,0.05）， and the level of CA199 in the treatment group was lower than that in the control group （,P,<,0.05）. ④After treatment， the levels of IL-1β and IL-6 in the two groups were decreased compared with those before treatment （,P,<,0.05）， the level of TNF-α in the treatment group was also decreased compared with that before treatment （,P,<,0.05）， and the levels of IL-1β and IL-6 in the treatment group were lower than those in the control group （,P,<,0.05）. ⑤During the treatment， the incidence of adverse reactions was 44.1% in the treatment group and was 76.5% in the control group. The incidence of adverse reactions in the treatment group was significantly lower than that in the control group （,P,<,0.05）.,Conclusion,2,Chemotherapy combined with modified Yiyanxiao Formula can effectively inhibit the expressions of tumor markers and inflammatory cytokines in the treatment of patients of pancreatic cancer with peritoneal metastasis， improve the clinical symptoms of the patients， increase the disease control rate， and decrease the incidence of adverse reactions of chemotherapy.

关键词

胰腺癌腹膜转移腹腔灌注化疗胰岩消方中西医结合

Keywords

pancreatic cancerperitoneal metastasisintraperitoneal perfusion chemotherapyYiyanxiao Formulaintegrated traditional Chinese and western medicine

references

刘宗超，李哲轩，张阳，等. 2020全球癌症统计报告解读［J］. 肿瘤综合治疗电子杂志， 2021， 7（2）： 1-13.

LIU Z C， LI Z X， ZHANG Y， et al. Interpretation on the report of Global Cancer Statistics 2020［J］. Journal of Multidisciplinary Cancer Management （Electronic Version）， 2021， 7（2）： 1-13.

LU Z， WANG J， WIENTJES M G， et al. Intraperitoneal therapy for peritoneal cancer［J］. Future Oncol， 2010， 6（10）： 1625-1641.

肝胆胰恶性肿瘤腹腔化疗专家组. 肝胆胰恶性肿瘤腹腔化疗专家共识（2020版）［J］. 中华肝脏外科手术学电子杂志， 2020， 9（6）： 522-528.

Expert Group of Intraperitoneal Chemotherapy for Hepatobiliary and Pancreatic Malignant Tumor. Expert consensus on intraperitoneal chemotherapy for hepatobiliary pancreatic malignancies （Version 2020）［J］. Chinese Journal of Hepatic Surgery （Electronic Edition）， 2020， 9（6）： 522-528.

中国临床肿瘤学会胰腺癌专家委员会. 胰腺癌综合诊治中国专家共识（2014年版）［J］. 临床肿瘤学杂志， 2014， 19（4）： 358-370.

Pancreatic cancer Expert Committee of Chinese Society of Clinical Oncology. Chinese expert consensus on comprehensive diagnosis and treatment of pancreatic cancer （2014 Edition）［J］. Chinese Clinical Oncology， 2014， 19（4）： 358-370.

中华人民共和国卫生部. 胰腺癌诊疗规范（2011年版）［J］. 临床肿瘤学杂志， 2011， 16（11）： 1026-1032.

Ministry of Health， PRC. Diagnosis and Treatment Specifications for pancreatic cancer （2011 Edition）［J］. Chinese Clinical Oncology， 2011， 16（11）： 1026-1032.

柳影，程颖. 实体肿瘤疗效评价标准的研究［J］. 实用肿瘤学杂志， 2004， 18（2）： 149-152.

LIU Y， CHENG Y. Study on evaluation criteria of curative effect of solid tumors［J］. Practical Oncology Journal， 2004， 18（2）： 149-152．

CELLA D F， TULSKY D S， GRAY G， et al. The Functional Assessment of Cancer Therapy scale： development and validation of the general measure［J］. J Clin Oncol， 1993， 11（3）： 570-579.

国家中医药管理局. 24个专业105个病种中医诊疗方案［M］. 北京：中国中医药出版社， 2011： 360-364.

State Administration of Traditional Chinese Medicine. TCM diagnosis and treatment plan for 105 diseases in 24 specialties［M］. Beijing： China Press of Traditional Chinese Medicine， 2011： 360-364.

宋叶，林东，梅全喜，等. 太子参化学成分及药理作用研究进展［J］. 中国药师， 2019， 22（8）： 1506-1510.

SONG Y， LIN D， MEI Q X， et al. Study advances in chemical constituents and pharmacological activities of radix pseudostellariae［J］. China Pharmacist， 2019， 22（8）： 1506-1510.

张晓娟，左冬冬. 白术化学成分及药理作用研究新进展［J］. 中医药信息， 2018， 35（6）： 101-106.

ZHANG X J， ZUO D D. New progress in research on chemical constituents and pharmacological effects of Atractylodes macrocephala［J］. Information on Traditional Chinese Medicine， 2018， 35（6）： 101-106.

谢士敏，周长征. 蒲公英药理作用及临床应用研究进展［J］. 辽宁中医药大学学报， 2020， 22（5）： 138-142.

XIE S M， ZHOU C Z. Research progress on pharmacological action and clinical application of Taraxacum Mongolicum Hand Mazz［J］. Journal of Liaoning University of Traditional Chinese Medicine， 2020， 22（5）： 138-142.

谢怡琼，王琪瑞，孙思雅，等. 灵芝的药理作用和临床应用研究进展［J］. 临床医学研究与实践， 2020， 5（10）： 191-193.

XIE Y Q， WANG Q R， SUN S Y， et al. Research progress on the pharmacological effects and clinical applications of Ganoderma lucidum［J］. Clinical Medical Research and Practice， 2020， 5（10）： 191-193.

李富龙，李雅南，高方毅，等. 胰岩消方加减联合化疗对晚期胰腺癌患者生存质量及生存期的影响［J］. 中医杂志， 2021， 62（10）： 887-892.

LI F L， LI Y N， GAO F Y， et al. Effect of modified Yi Yan Xiao formula combined with chemotherapy on quality of life and survival time in patients with advanced pancreatic cancer［J］. Journal of Traditional Chinese Medicine， 2021， 62（10）： 887-892.

崔大鹏，王玉佳，韩磊，等. CA19-9、CEA、CA125及sICAM-1对胰腺癌的诊断价值分析及其与肿瘤转移的相关性研究［J］. 国际外科学杂志， 2018， 45（1）： 10-15.

CUI D P， WANG Y J， HAN L， et al. Relationship analysis of serum CA19-9， CEA， CA125 and sICAM-1 with the diagnosis valuation and tumor metastasis of pancreatic cancer［J］. International Journal of Surgery， 2018， 45（1）： 10-15.

郭李娜，秦刚，郭弘. 血清CA199、CA125和CEA联合检测对胰腺癌的诊断价值［J］. 中国实用医刊， 2018， 45（3）： 60-62.

GUO L N， QIN G， GUO H. Value of combined detection of serum CA199， CA125 and CEA in the diagnosis of pancreatic cancer［J］. Chinese Journal of Practical Medicine， 2018， 45（3）： 60-62．

王勇，杨丽，韩际奥. 血清CA19-9联合CT检查胰腺癌的临床价值分析［J］. 中华老年医学杂志， 2019， 38（4）： 416-418.

WANG Y， YANG L， HAN J. Diagnostic value of combined serum CA19-9 with CT scanning in patients with pancreatic cancer［J］. Chinese Journal of Geriatrics， 2019， 38（4）： 416-418．

Views

129

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Renal Failure Ⅱ Prescription granule combined with empagliflozin on proteinuria and renal function in patients with CKD at stages 2⁃3

Expert consensus on integrated traditional Chinese and western medicine clinical diagnosis and treatment of brain glioma （Shanghai）

Clinical observation of Shenshuaiyi Formula in treatment of chronic kidney disease at stage 4 combined with chronic heart failure

Clinical research on Xiaobai Decoction in the treatment of chronic glomerulonephritis (CKD at stages 1-2) with syndrome of spleen and kidney qi deficiency and stagnant dampness-heat

Clinical efficacy of Shuxin Oral Liquid combined with conventional western medicine in the treatment of stable coronary heart disease with anxiety based on "psycho-cardiology disease" theory

Related Author

No data

Related Institution

Department of Nephrology， Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine； Shanghai Clinical Key Laboratory of Traditional Chinese Medicine； Key Laboratory of Liver and Kidney Diseases， Ministry of Education

Yidan Nursing Home

Inheritance Studio of Ye Jinghua National Famous Doctor of Traditional Chinese Medicine

Department of Nephrology， the Seventh People’s Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; TCM Institute of Kidney Disease, Shanghai University of Traditional Chinese Medicine; Key Laboratory of Liver and Kidney Diseases, Ministry of Education

⁰